Pharmaceutical

Orphan drug market access in Europe: HTA challenges and the growing potential of RWE

Orphan drug developers face significant difficulties when navigating market access frameworks in Europe. Could greater use of real-world evidence help close the evidence gap?

May 14, 2025 - 06:00
Orphan drug market access in Europe: HTA challenges and the growing potential of RWE
Orphan drug developers face significant difficulties when navigating market access frameworks in Europe. Could greater use of real-world evidence help close the evidence gap?
Read the original article

Tags:

Previous Article

Japan’s MHLW approves Sarepta’s gene therapy for DMD

Next Article

Reducing patient burden in rare disease trials: DCTs for increased patient centr...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: RNA startup ReNAgade cuts staff seven months after raising $300 million

STAT+: RNA startup ReNAgade cuts staff seven months aft...

Dec 5, 2023

When young people survive cancer, their mental-health struggles are often just beginning

When young people survive cancer, their mental-health s...

Jun 28, 2023

STAT+: Liver disease MASH is next target for obesity drugs in development

STAT+: Liver disease MASH is next target for obesity dr...

Feb 27, 2024